Cargando…

Discovery of E2730, a novel selective uncompetitive GAT1 inhibitor, as a candidate for anti‐seizure medication

OBJECTIVE: As of 2022, 36 anti‐seizure medications (ASMs) have been licensed for the treatment of epilepsy, however, adverse effects (AEs) are commonly reported. Therefore, ASMs with a wide margin between therapeutic effects and AEs are preferred over ASMs that are associated with a narrow margin be...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukushima, Kazuyuki, Higashiyama, Hiroyuki, Kazuta, Yuji, Hashimoto, Keisuke, Watanabe, Naoto, Furuya, Yoshiaki, Ito, Yoshimasa, Wu, Ting, Kosasa, Takashi, Talos, Delia M., Song, Yeri, Roberts, Nicholas S., Jensen, Frances E., Hanada, Takahisa, Ido, Katsutoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472371/
https://www.ncbi.nlm.nih.gov/pubmed/37052238
http://dx.doi.org/10.1002/epi4.12741
_version_ 1785100061773922304
author Fukushima, Kazuyuki
Higashiyama, Hiroyuki
Kazuta, Yuji
Hashimoto, Keisuke
Watanabe, Naoto
Furuya, Yoshiaki
Ito, Yoshimasa
Wu, Ting
Kosasa, Takashi
Talos, Delia M.
Song, Yeri
Roberts, Nicholas S.
Jensen, Frances E.
Hanada, Takahisa
Ido, Katsutoshi
author_facet Fukushima, Kazuyuki
Higashiyama, Hiroyuki
Kazuta, Yuji
Hashimoto, Keisuke
Watanabe, Naoto
Furuya, Yoshiaki
Ito, Yoshimasa
Wu, Ting
Kosasa, Takashi
Talos, Delia M.
Song, Yeri
Roberts, Nicholas S.
Jensen, Frances E.
Hanada, Takahisa
Ido, Katsutoshi
author_sort Fukushima, Kazuyuki
collection PubMed
description OBJECTIVE: As of 2022, 36 anti‐seizure medications (ASMs) have been licensed for the treatment of epilepsy, however, adverse effects (AEs) are commonly reported. Therefore, ASMs with a wide margin between therapeutic effects and AEs are preferred over ASMs that are associated with a narrow margin between efficacy and risk of AEs. E2730 was discovered using in vivo phenotypic screening and characterized as an uncompetitive, yet selective, inhibitor of γ‐aminobutyric acid (GABA) transporter 1 (GAT1). Here, we describe the preclinical characteristics of E2730. METHODS: Anti‐seizure effects of E2730 were evaluated in several animal models of epilepsy: corneal kindling, 6 Hz–44 mA psychomotor seizure, amygdala kindling, Fragile X syndrome, and Dravet syndrome models. Effects of E2730 on motor coordination were assessed in accelerating rotarod tests. The mechanism of action of E2730 was explored by [(3)H]E2730 binding assay. The GAT1‐selectivity over other GABA transporters was examined by GABA uptake assay of GAT1, GAT2, GAT3, or betaine/GABA transporter 1 (BGT‐1) stably expressing HEK293 cells. To further investigate the mechanism for E2730‐mediated inhibition of GAT1, in vivo microdialysis and in vitro GABA uptake assays were conducted under conditions of different GABA concentrations. RESULTS: E2730 showed anti‐seizure effects in the assessed animal models with an approximately >20‐‍fold margin between efficacy and motor incoordination. [(3)H]E2730 binding on brain synaptosomal membrane was abolished in GAT1‐deficient mice, and E2730 selectively inhibited GAT1‐mediated GABA uptake over other GABA transporters. In addition, results of GABA uptake assays showed that E2730‐mediated inhibition of GAT1 positively correlated to the level of ambient GABA in vitro. E2730 also increased extracellular GABA concentration in hyperactivated conditions but not under basal levels in vivo. SIGNIFICANCE: E2730 is a novel, selective, uncompetitive GAT1 inhibitor, which acts selectively under the condition of increasing synaptic activity, contributing to a wide margin between therapeutic effect and motor incoordination.
format Online
Article
Text
id pubmed-10472371
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-104723712023-09-02 Discovery of E2730, a novel selective uncompetitive GAT1 inhibitor, as a candidate for anti‐seizure medication Fukushima, Kazuyuki Higashiyama, Hiroyuki Kazuta, Yuji Hashimoto, Keisuke Watanabe, Naoto Furuya, Yoshiaki Ito, Yoshimasa Wu, Ting Kosasa, Takashi Talos, Delia M. Song, Yeri Roberts, Nicholas S. Jensen, Frances E. Hanada, Takahisa Ido, Katsutoshi Epilepsia Open Original Articles OBJECTIVE: As of 2022, 36 anti‐seizure medications (ASMs) have been licensed for the treatment of epilepsy, however, adverse effects (AEs) are commonly reported. Therefore, ASMs with a wide margin between therapeutic effects and AEs are preferred over ASMs that are associated with a narrow margin between efficacy and risk of AEs. E2730 was discovered using in vivo phenotypic screening and characterized as an uncompetitive, yet selective, inhibitor of γ‐aminobutyric acid (GABA) transporter 1 (GAT1). Here, we describe the preclinical characteristics of E2730. METHODS: Anti‐seizure effects of E2730 were evaluated in several animal models of epilepsy: corneal kindling, 6 Hz–44 mA psychomotor seizure, amygdala kindling, Fragile X syndrome, and Dravet syndrome models. Effects of E2730 on motor coordination were assessed in accelerating rotarod tests. The mechanism of action of E2730 was explored by [(3)H]E2730 binding assay. The GAT1‐selectivity over other GABA transporters was examined by GABA uptake assay of GAT1, GAT2, GAT3, or betaine/GABA transporter 1 (BGT‐1) stably expressing HEK293 cells. To further investigate the mechanism for E2730‐mediated inhibition of GAT1, in vivo microdialysis and in vitro GABA uptake assays were conducted under conditions of different GABA concentrations. RESULTS: E2730 showed anti‐seizure effects in the assessed animal models with an approximately >20‐‍fold margin between efficacy and motor incoordination. [(3)H]E2730 binding on brain synaptosomal membrane was abolished in GAT1‐deficient mice, and E2730 selectively inhibited GAT1‐mediated GABA uptake over other GABA transporters. In addition, results of GABA uptake assays showed that E2730‐mediated inhibition of GAT1 positively correlated to the level of ambient GABA in vitro. E2730 also increased extracellular GABA concentration in hyperactivated conditions but not under basal levels in vivo. SIGNIFICANCE: E2730 is a novel, selective, uncompetitive GAT1 inhibitor, which acts selectively under the condition of increasing synaptic activity, contributing to a wide margin between therapeutic effect and motor incoordination. John Wiley and Sons Inc. 2023-05-18 /pmc/articles/PMC10472371/ /pubmed/37052238 http://dx.doi.org/10.1002/epi4.12741 Text en © 2023 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Fukushima, Kazuyuki
Higashiyama, Hiroyuki
Kazuta, Yuji
Hashimoto, Keisuke
Watanabe, Naoto
Furuya, Yoshiaki
Ito, Yoshimasa
Wu, Ting
Kosasa, Takashi
Talos, Delia M.
Song, Yeri
Roberts, Nicholas S.
Jensen, Frances E.
Hanada, Takahisa
Ido, Katsutoshi
Discovery of E2730, a novel selective uncompetitive GAT1 inhibitor, as a candidate for anti‐seizure medication
title Discovery of E2730, a novel selective uncompetitive GAT1 inhibitor, as a candidate for anti‐seizure medication
title_full Discovery of E2730, a novel selective uncompetitive GAT1 inhibitor, as a candidate for anti‐seizure medication
title_fullStr Discovery of E2730, a novel selective uncompetitive GAT1 inhibitor, as a candidate for anti‐seizure medication
title_full_unstemmed Discovery of E2730, a novel selective uncompetitive GAT1 inhibitor, as a candidate for anti‐seizure medication
title_short Discovery of E2730, a novel selective uncompetitive GAT1 inhibitor, as a candidate for anti‐seizure medication
title_sort discovery of e2730, a novel selective uncompetitive gat1 inhibitor, as a candidate for anti‐seizure medication
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472371/
https://www.ncbi.nlm.nih.gov/pubmed/37052238
http://dx.doi.org/10.1002/epi4.12741
work_keys_str_mv AT fukushimakazuyuki discoveryofe2730anovelselectiveuncompetitivegat1inhibitorasacandidateforantiseizuremedication
AT higashiyamahiroyuki discoveryofe2730anovelselectiveuncompetitivegat1inhibitorasacandidateforantiseizuremedication
AT kazutayuji discoveryofe2730anovelselectiveuncompetitivegat1inhibitorasacandidateforantiseizuremedication
AT hashimotokeisuke discoveryofe2730anovelselectiveuncompetitivegat1inhibitorasacandidateforantiseizuremedication
AT watanabenaoto discoveryofe2730anovelselectiveuncompetitivegat1inhibitorasacandidateforantiseizuremedication
AT furuyayoshiaki discoveryofe2730anovelselectiveuncompetitivegat1inhibitorasacandidateforantiseizuremedication
AT itoyoshimasa discoveryofe2730anovelselectiveuncompetitivegat1inhibitorasacandidateforantiseizuremedication
AT wuting discoveryofe2730anovelselectiveuncompetitivegat1inhibitorasacandidateforantiseizuremedication
AT kosasatakashi discoveryofe2730anovelselectiveuncompetitivegat1inhibitorasacandidateforantiseizuremedication
AT talosdeliam discoveryofe2730anovelselectiveuncompetitivegat1inhibitorasacandidateforantiseizuremedication
AT songyeri discoveryofe2730anovelselectiveuncompetitivegat1inhibitorasacandidateforantiseizuremedication
AT robertsnicholass discoveryofe2730anovelselectiveuncompetitivegat1inhibitorasacandidateforantiseizuremedication
AT jensenfrancese discoveryofe2730anovelselectiveuncompetitivegat1inhibitorasacandidateforantiseizuremedication
AT hanadatakahisa discoveryofe2730anovelselectiveuncompetitivegat1inhibitorasacandidateforantiseizuremedication
AT idokatsutoshi discoveryofe2730anovelselectiveuncompetitivegat1inhibitorasacandidateforantiseizuremedication